

PURPLE TEAM PILOT

- Intel Corporation
- iSolve
- Excellis Health

“Creating a 360° View of the Biopharma Supply Chain with Digital Ledger Technology”

Overview

This pilot is designed to demonstrate how digital ledger technology is *complimentary* to existing track & trace solutions. It demonstrates a blockchain-based, end-to-end tracking solution (from manufacturer to patient) that can be used to easily transfer data from one party to another, improve operational efficiency, and create a positive impact on patient outcomes.

Team's vision

The Purple Team's mission for its PoC Pilot is to take a holistic view of the supply chain – linking manufacturer to patient by building an interoperable connection between all trusted participants in a modern biopharma supply chain, including:

- Manufacturer
- Wholesaler
- Pharmacy/dispenser (health system, community/rural hospital, retail)
- Patient

DSCSA focus

The Team demonstrates a fully viable 2023 interoperable solution that meets the regulatory requirements of DSCSA and beyond. Specifically, this PoC addresses:

1. Consumer protection from counterfeit, stolen, contaminated, or otherwise harmful medications
2. Track & trace of prescription medications throughout the US and global supply chains
3. Improvements detection and removal of potentially dangerous drugs from the drug supply chain

Pilot will demo:

- Interoperability
- Saleable returns
- Drug recall
- Supply chain integrity
- Borrow and loan
- End-to-end track & trace solution

Target audience

Since this pilot demonstration also addresses the impact on the FDA and how it can assist other EPCIS solution providers, all stakeholders in a modern biopharma supply chain can benefit from this potential blockchain-based solution.

	Manufacturer	Distributor	Pharmacy/Retailer/Disp	Patient
DSCSA compliance	✓	✓	✓	
Reduce counterfeit drugs	✓	✓	✓	✓
Improve patient safety	✓	✓	✓	✓
Improve transparency, operations	✓	✓	✓	✓
Protect brand	✓		✓	
Verify drug authenticity, provenance, safety	✓	✓	✓	✓

Technical features

The Purple Team will evaluate the quality and speed of writing and reading to the ADLT™ platform and explain how other technology can be integrated for a 360° view of the biopharma supply chain by addressing key business processes such as saleable returns, borrow/loan, drug recall and supply chain integrity. The team also will demonstrate how the ADLT™ platform is *complementary to – and not a replacement for*–existing systems and processes.

The pilot will exhibit how the data source (manufacturer, wholesaler, pharmacy, patient) will transmit EPCIS data via a secure API connection to a cloud based ADLT™– Sawtooth Lake Node. Each node will be specific for a member of the biopharma supply chain.